NASDAQ$NKGN

Nkgen Biotech Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

NKGN Q2 2024 — $1.24B revenue, 0.67 EPS

These forward-looking statements involve a number of risks, uncertainties (many of which are difficult to predict and beyond the Company’s control) or other assumptions that may cause actual results o. Nkgen Biotech Inc reported Q2 2024 results. Diluted EPS came in at $0.67. Net income of $21.5M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $1.24B.
  • Diluted EPS: $0.67.
  • Net income: $21.5M.
  • Operating income: $7K.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.67

Previous: -$0.59-13.6%
Capital Expenditures

-$15K

Previous: $0.00
Net Income

-$16.1M

Previous: -$1.83M-778.6%
Operating Income

-$7.46M

Previous: -$2.68M-178.6%
Gross Profit

-$326K

Previous: $0.00
R&D Expense

$2.79M

No prior period
Stock-Based Comp

$1.1M

Previous: $982K+11.7%

Revenue & EPS history

Nkgen Biotech · Revenue · Quarterly

$0

Q2 2024

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+6.0%

Avg return

Earnings day

-0.7%

Avg return

5 days after

+2.7%

Avg return

30 days after

41%

7 / 17 earnings

Positive

+57.1%

Q1 2024

Best reaction

-16.9%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025+0.0%+0.0%+0.0%
Q1 2025+0.0%+0.0%+0.0%
Q2 2025+0.0%+0.0%+85.0%
Q4 2024+21.4%+0.0%-5.0%
Q3 2024+36.1%+4.7%-5.8%
Q2 2024-0.8%-37.1%-64.1%
Q1 2024+57.1%+26.8%+6.3%
Q4 2023-16.9%-10.8%-8.9%
Q3 2023+5.1%+2.6%+37.9%
Q2 2023+0.3%+0.8%-2.9%
Q1 2023+0.3%-0.3%+0.0%
Q4 2022+0.3%-0.3%+0.0%
Q3 2022-0.3%+0.3%+0.5%
Q2 2022+0.0%+0.0%-0.1%
Q1 2022+0.0%+0.3%+0.7%
Q4 2021+0.0%+0.3%+0.7%
Q3 2021+0.0%+0.2%+1.0%
Q1 2021

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro